Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to investigate antiviral activity, safety and pharmacokinetics
of 5 days of monotherapy with BI 207127 in HCV genotype 1 (GT1) infected patients. Both
treatment-naïve patients and patients previously treated with peginterferon and ribavirin
were included. In addition, the effect of study medication was examined in a group of
patients with liver cirrhosis.